Search Results - "Stuart ASV"

Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.

Authors: Patrick-Smith M Emary K Hodgson SH et al.

Source: Vaccine [Vaccine] 2024 Dec 02; Vol. 42 (26), pp. 126391. Date of Electronic Publication: 2024 Oct 01.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months.

Authors: Langley, Joanne M Nolan, Terry M Rämet, Mika et al.

Source: Open Forum Infectious Diseases. Sep2024, Vol. 11 Issue 9, p1-10. 10p.

Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.

Authors: Cervantes-Torres, Jacquelynne Cabello-Gutiérrez, Carlos Ayón-Núñez, Dolores-Adriana et al.

Source: Applied Microbiology & Biotechnology; 1/27/2024, Vol. 108 Issue 1, p1-15, 15p

A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.

Authors: Kulkarni, Prasad S. Gunale, Bhagwat Kohli, Sunil et al.

Source: Scientific Reports. 11/20/2023, Vol. 13 Issue 1, p1-14. 14p.

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Authors: Stuart ASV Virta M Williams K et al.

Source: The Journal of infectious diseases [J Infect Dis] 2022 Dec 28; Vol. 227 (1), pp. 71-82.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE

Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population.

Authors: Carrat, Fabrice Villarroel, Paola Mariela Saba Lapidus, Nathanael et al.

Source: Scientific Reports. 6/7/2022, Vol. 12 Issue 1, p1-10. 10p.

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Authors: Shaw RH Greenland M Stuart ASV et al.

Corporate Authors: Shaw RH Greenland M Stuart ASV et al.

Source: The Journal of infection [J Infect] 2023 Jun; Vol. 86 (6), pp. 574-583. Date of Electronic Publication: 2023 Apr 06.

Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: W.B. Saunders Country of Publication: England NLM ID: 7908424 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2742 (Electronic) Linking ISSN: 01634453 NLM ISO Abbreviation: J Infect Subsets: MEDLINE

Immunological pathogenesis and treatment progress of adenovirus pneumonia in children.

Authors: Liang, Yaowen Wei, Jie Shen, Jianjun et al.

Source: Italian Journal of Pediatrics. 1/9/2025, Vol. 51 Issue 1, p1-14. 14p.

Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.

Authors: Ward, Daniel Pattarapreeyakul, Lapasrada Pitaksalee, Rujiraporn et al.

Source: Scientific Reports. 1/9/2025, Vol. 15 Issue 1, p1-14. 14p.

Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.

Authors: Chaiwarith, Romanee Winichakoon, Poramed Salee, Parichat et al.

Source: Scientific Reports. 11/13/2023, Vol. 13 Issue 1, p1-11. 11p.

Core protocol for the adaptive Platform Trial In COVID-19 Vaccine priming and BOOsting (PICOBOO).

Authors: McLeod, C. Ramsay, J Flanagan, K. L. et al.

Source: Trials. 3/18/2023, Vol. 24 Issue 1, p1-14. 14p. 5 Charts.

How inclusive were UK-based randomised controlled trials of COVID-19 vaccines? A systematic review investigating enrolment of Black adults and adult ethnic minorities.

Authors: Herieka, Hibba Babalis, Daphne Tzala, Evangelia et al.

Source: Trials. 4/12/2024, p1-10. 10p.

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion.

Authors: Qin, Zhen Bouteau, Aurélie Herbst, Christopher et al.

Source: PLoS Pathogens. 9/2/2022, Vol. 18 Issue 9, p1-23. 23p.

Clinical trials of pharmacological interventions for SARS-CoV-2 published in leading medical journals report adherence but not how it was assessed.

Authors: Lee C Otunla A Brennan I et al.

Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Apr; Vol. 90 (4), pp. 1130-1141. Date of Electronic Publication: 2024 Jan 25.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE

The effects of Chinese proprietary medicine and vaccination on patients with COVID-19: a retrospective study in Macao.

Authors: Mo, Hui Zhou, Man-Fei Lao, Edmundo Patricio Lopes et al.

Source: Chinese Medicine. 1/23/2024, Vol. 19 Issue 1, p1-12. 12p.

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].

Authors: Poh, Xuan Ying Lee, I. Russel Lim, Clarissa et al.

Source: Trials. 6/16/2022, Vol. 23 Issue 1, p1-13. 13p. 3 Charts.

COVID-19: prevención, diagnóstico y tratamiento. Recomendaciones de un grupo multidisciplinario.

Alternate Title: COVID-19: prevention, diagnosis and treatment. Recommendations of a multidisciplinary group.

Authors: Ortiz-Ibarra, Federico Javier Campos-Campos, Jesús Abraham Simón Macías-Hernández, Alejandro et al.

Source: Medicina Interna de México. mar/abr2022, Vol. 38 Issue 2, p288-321. 34p.

Distinguishing the Vaccine Effectiveness of Inactivated BBIBP-CorV Vaccine Booster Against the Susceptibility, Infectiousness, and Transmission of Omicron Stains: A Retrospective Cohort Study in Urumqi, China.

Authors: Zeng, Ting Wang, Kailu Guo, Zihao et al.

Source: Infectious Diseases & Therapy. Oct2023, Vol. 12 Issue 10, p2405-2416. 12p.

Ethnic minority representation in UK COVID-19 trials: systematic review and meta-analysis.

Authors: Murali, Mayur Gumber, Leher Jethwa, Hannah et al.

Source: BMC Medicine. 8/15/2023, Vol. 21 Issue 1, p1-18. 18p.

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Authors: Stuart ASV Shaw RH Liu X et al.

Corporate Authors: Stuart ASV Shaw RH Liu X et al.

Source: Lancet (London, England) [Lancet] 2022 Jan 01; Vol. 399 (10319), pp. 36-49. Date of Electronic Publication: 2021 Dec 06.

Publication Type: Clinical Trial, Phase II; Equivalence Trial; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE